Amgen Announces Appointment of Robert A. Eckert to Board of
Directors
THOUSAND OAKS, Calif.,
Dec. 13, 2012 /PRNewswire/ -- Amgen
(NASDAQ: AMGN) today announced the appointment of Robert A. Eckert, former chief executive officer
at Mattel, Inc., to its Board of Directors. Mr. Eckert will serve
on the Audit and Corporate Responsibility and Compliance Committees
of the Board. Following the appointment of Mr. Eckert and the
previously announced retirement of Kevin W.
Sharer from the Board on Dec. 31,
2012, the Board on Jan. 1,
2013, will be comprised of 14 directors, 13 of whom are
independent.
"We are pleased to welcome Bob
Eckert to the Amgen Board. Bob has significant experience
and a superb track record of leading global companies during a long
and successful career," said Robert A.
Bradway, chief executive officer at Amgen. "His
contributions to the Board will guide us as we expand our reach to
more patients in more markets and continue creating value for our
stockholders."
Robert A. Eckert
Mr. Eckert, 58, currently serves as non-executive Chairman at
Mattel, Inc., where he served as Chief Executive Officer from 2000
through 2011. Prior to this role, Mr. Eckert was President and
Chief Executive Officer of Kraft Foods, Inc. from 1997 to 2000.
Before that, Mr. Eckert served as Group Vice President and
President of Kraft's Oscar Mayer
foods division. Mr. Eckert currently serves on the Boards of
Directors of McDonald's Corporation and Levi Strauss & Co.
Mr. Eckert is on the Dean's Advisory Board of the Kellogg
Graduate School of Management and serves on the Eller College of
Management National Board of Advisors at the University of Arizona. Mr. Eckert holds a Bachelor
of Arts degree from the University of
Arizona and an MBA from Northwestern
University.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative
human therapeutics. A biotechnology pioneer since 1980, Amgen was
one of the first companies to realize the new science's promise by
bringing safe and effective medicines from lab, to manufacturing
plant, to patient. Amgen therapeutics have changed the practice of
medicine, helping millions of people around the world in the fight
against cancer, kidney disease, rheumatoid arthritis, bone disease
and other serious illnesses. With a deep and broad pipeline of
potential new medicines, Amgen remains committed to advancing
science to dramatically improve people's lives. To learn more about
our pioneering science and our vital medicines, visit
www.amgen.com. Follow us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Ashleigh Koss, 805-313-6151
(media)
Arvind Sood, 805-447-1060
(investors)
(Logo:
http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)
SOURCE Amgen